1. André, F, Su, F, Solovieff, N, Slamon, D, Arteaga, C L. 2023. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. In Annals of oncology : official journal of the European Society for Medical Oncology, 34, 1003-1014. doi:10.1016/j.annonc.2023.08.011. https://pubmed.ncbi.nlm.nih.gov/37673211/
2. Jing, Wenyi, Lan, Ting, Qiu, Yan, Chen, Chen, Zhang, Hongying. 2021. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data. In Diagnostic pathology, 16, 96. doi:10.1186/s13000-021-01161-9. https://pubmed.ncbi.nlm.nih.gov/34696768/
3. Zhu, Yan, Liu, Ziying, Cao, Lili, Wang, Yicun, Zhou, Guangxin. 2023. FRS2 regulated by miR-429 and miR-206 promotes angiogenesis in osteosarcoma. In Gene, 898, 148118. doi:10.1016/j.gene.2023.148118. https://pubmed.ncbi.nlm.nih.gov/38159618/
4. Saba, Karim H, Difilippo, Valeria, Styring, Emelie, Baumhoer, Daniel, Nord, Karolin H. 2024. CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma. In NPJ genomic medicine, 9, 42. doi:10.1038/s41525-024-00430-y. https://pubmed.ncbi.nlm.nih.gov/39322633/
5. Valencia, Tania, Joseph, Ajay, Kachroo, Naveen, Meakin, Susan, Gnanapragasam, Vincent J. 2011. Role and expression of FRS2 and FRS3 in prostate cancer. In BMC cancer, 11, 484. doi:10.1186/1471-2407-11-484. https://pubmed.ncbi.nlm.nih.gov/22078327/
6. He, Xin, Pang, Zongguo, Zhang, Xianliang, Peng, Ran, Zhang, Hongying. . Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis. In The American journal of surgical pathology, 42, 1143-1155. doi:10.1097/PAS.0000000000001125. https://pubmed.ncbi.nlm.nih.gov/30001240/
7. Zhong, XiaoRong, Xie, GuiQin, Zhang, Zhang, Li, JiaYuan, Zheng, Hong. . MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. In Oncotarget, 7, 61166-61182. doi:10.18632/oncotarget.11278. https://pubmed.ncbi.nlm.nih.gov/27533459/
8. Jing, Wenyi, Lan, Ting, Chen, Huijiao, He, Xin, Zhang, Hongying. 2018. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases. In Histopathology, 72, 1145-1155. doi:10.1111/his.13473. https://pubmed.ncbi.nlm.nih.gov/29368794/
智鼠故事 
